Lower neck radiation dose for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests if giving a lower dose of radiation to the neck area (where the cancer hasn't spread) is just as safe and effective as the standard dose in people with nasopharyngeal cancer. The goal is to reduce side effects while maintaining cancer control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with nasopharyngeal carcinoma (a type of cancer in the back of the nose/throat).
- Your cancer has not spread to other parts of the body.
- You are generally able to take care of yourself (ECOG score 0 or 1).
- You have not had another cancer in the last 5 years (except some skin or early cervical cancers).
- You do not have serious health issues like uncontrolled high blood pressure, heart disease, or an active infection.
- You are not pregnant or breastfeeding, and you are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
This Phase 2 study tests whether using a special scan (PET/CT) to guide radiation can safely reduce the radiation dose for people with nasopharyngeal cancer. It may help lessen side effects while still treating the cancer effectively.
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
This trial tests whether giving a lower dose of radiation to the main tumor is safe and effective for people with nasopharyngeal cancer (a type of nose/throat cancer) who first receive a combination of immunotherapy (toripalimab) and chemotherapy. It aims to reduce side effects while still controlling the cancer.
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.